FR3039403B1 - XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS - Google Patents

XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS

Info

Publication number
FR3039403B1
FR3039403B1 FR1557288A FR1557288A FR3039403B1 FR 3039403 B1 FR3039403 B1 FR 3039403B1 FR 1557288 A FR1557288 A FR 1557288A FR 1557288 A FR1557288 A FR 1557288A FR 3039403 B1 FR3039403 B1 FR 3039403B1
Authority
FR
France
Prior art keywords
mnesic
xenon
functionality
loss
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1557288A
Other languages
French (fr)
Other versions
FR3039403A1 (en
Inventor
Etienne Hirsch
Jeremie Lavaur
Marc Lemaire
Patrick Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Institut du Cerveau et de La Moelle Epiniere ICM
Original Assignee
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Institut du Cerveau et de La Moelle Epiniere ICM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide SA, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude, Institut du Cerveau et de La Moelle Epiniere ICM filed Critical Air Liquide SA
Priority to FR1557288A priority Critical patent/FR3039403B1/en
Priority to PCT/FR2016/051920 priority patent/WO2017017363A1/en
Publication of FR3039403A1 publication Critical patent/FR3039403A1/en
Application granted granted Critical
Publication of FR3039403B1 publication Critical patent/FR3039403B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1557288A 2015-07-30 2015-07-30 XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS Expired - Fee Related FR3039403B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1557288A FR3039403B1 (en) 2015-07-30 2015-07-30 XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS
PCT/FR2016/051920 WO2017017363A1 (en) 2015-07-30 2016-07-22 Xenon-based inhalable drug to fight memory impairment caused by a loss of cholinergic neuron function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1557288A FR3039403B1 (en) 2015-07-30 2015-07-30 XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS

Publications (2)

Publication Number Publication Date
FR3039403A1 FR3039403A1 (en) 2017-02-03
FR3039403B1 true FR3039403B1 (en) 2018-07-13

Family

ID=54145933

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1557288A Expired - Fee Related FR3039403B1 (en) 2015-07-30 2015-07-30 XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS

Country Status (2)

Country Link
FR (1) FR3039403B1 (en)
WO (1) WO2017017363A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
AU2014233018A1 (en) * 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3007983B1 (en) * 2013-07-08 2015-06-26 Air Liquide ASSOCIATION OF XENON AND AN NMDA RECEPTOR ANTAGONIST TO FIGHT NEURODEGENERATIVE DISEASE

Also Published As

Publication number Publication date
WO2017017363A1 (en) 2017-02-02
FR3039403A1 (en) 2017-02-03

Similar Documents

Publication Publication Date Title
HRP20210516T1 (en) Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
HK1212632A1 (en) Pharmaceutical compositions for the treatment of cftr mediated diseases cftr
IL246833A0 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
HK1231390A1 (en) Pharmaceutical composition for topical administration
EP3200877A4 (en) Low dose oral pharmaceutical composition of isotretinoin
EP3346996A4 (en) Oral pharmaceutical dosage forms of budesonide
EP3375443A4 (en) Pharmaceutical composition for treating respiratory diseases
HK1245646A1 (en) Pharmaceutical composition for oral administration
ZA201700843B (en) Oral pharmaceutical composition of isotretinoin
EP3250199A4 (en) A pharmaceutical composition for treating gastrointestinal diseases
FR3039403B1 (en) XENON-BASED INHALABLE MEDICINAL PRODUCT FOR CONTROLLING MNESIC DEFICITS CAUSED BY LOSS OF FUNCTIONALITY OF CHOLINERGIC NEURONS
PL3650024T3 (en) Pharmaceutical composition for nasal administration comprising rifampicins for treating dementia
IL260425B (en) New compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them
HK1232144A1 (en) Pharmaceutical composition for oral administration
EP3138567A4 (en) Pharmaceutical composition for treating chronic obstructive pulmonary diseases

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170203

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20240305